Regulation of cellular states via targeted phosphorylation of p53 using a nanobody-coupled kinase system

Phosphorylation participates in numerous signal transduction processes, including proliferation, differentiation, apoptosis, and cellular response to stimuli. Understanding its regulatory mechanisms is essential for advancing therapeutic interventions. In this study, we developed a target protein phosphorylation (TPP) system, consisting of a nanobody fused to a kinase domain, to investigate its ability to phosphorylate target proteins and regulate their cellular characteristics. We first verified that the nanobody-coupled kinase effectively phosphorylates GFP. Subsequently, we focused on p53 phosphorylation, identifying specific phosphorylation sites targeted by the system. This phosphorylation resulted in stabilization of p53 protein levels, inducing p21 expression, delaying cell cycle progression and suppressing cell growth. Furthermore, combining the TPP system with chemotherapeutic drugs (5-Fluorouracil and Oxaliplatin) enhanced cytotoxicity in colorectal cancer cells. The TPP system achieved p53 phosphorylation without external stimuli, inducing a DNA-damaged state in cells. In vivo, doxycycline-induced expression of the TPP system in a xenograft mouse model significantly inhibited tumor growth. This work demonstrates the ability to phosphorylate key regulatory proteins and alter cellular states, suggesting applications in studying phosphorylation-related pathways and developing therapies for diseases associated with dysregulated phosphorylation.

• Publication year

  2025

• Venue

  Cell Death Discovery

• Publication date

  2025-11-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41420-025-02821-1PMID 41213914PMCID 12603232
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting p53 pathways: mechanisms, structures and advances in therapy

  2023cited by this paper
• Cell cycle regulation: p53-p21-RB signaling

  2022cited by this paper
• Molecular targeted therapy for anticancer treatment

  2022cited by this paper
• Drugging p53 in cancer: one protein, many targets

  2022cited by this paper
• p53 signaling in cancer progression and therapy

  2021cited by this paper
• Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics

  2020cited by this paper
• Mutant p53 on the Path to Metastasis.

  2020cited by this paper
• Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia

  2018cited by this paper
• How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?

  2017cited by this paper
• Phosphorylation: Implications in Cancer

  2017cited by this paper
• Nanobody-targeted E3-ubiquitin ligase complex degrades nuclear proteins

  2015cited by this paper
• A nanobody modulates the p53 transcriptional program without perturbing its functional architecture

  2014cited by this paper
• Contribution of p53 to metastasis.

  2014cited by this paper
• Nanobodies: natural single-domain antibodies.

  2013cited by this paper
• Serum Starvation Induced Cell Cycle Synchronization Facilitates Human Somatic Cells Reprogramming

  2012cited by this paper
• p21 in cancer: intricate networks and multiple activities

  2009cited by this paper
• Functional Dynamics of Polo-Like Kinase 1 at the Centrosome

  2009cited by this paper
• Blinded by the Light: The Growing Complexity of p53.

  2009cited by this paper
• Modes of p53 regulation.

  2009cited by this paper
• Mechanisms of specificity in protein phosphorylation

  2007cited by this paper
• Mechanisms of specificity in protein phosphorylation

  2007cited by this paper
• Dysregulation of Protein Phosphorylation/Dephosphorylation in Alzheimer's Disease: A Therapeutic Target

  2006cited by this paper
• Targeting and tracing antigens in live cells with fluorescent nanobodies

  2006cited by this paper
• The complexity of p53 stabilization and activation

  2006cited by this paper
• The p53 pathway: positive and negative feedback loops

  2005cited by this paper
• Phosphorylation of Plk1 at S137 and T210 is Inhibited in Response to DNA Damage

  2005cited by this paper
• p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa

  2003cited by this paper
• 5-Fluorouracil: mechanisms of action and clinical strategies

  2003cited by this paper
• Gadd45a contributes to p53 stabilization in response to DNA damage

  2003cited by this paper
• The Protein Kinase Complement of the Human Genome

  2002cited by this paper
• PUMA, a novel proapoptotic gene, is induced by p53.

  2001cited by this paper
• Stress Signals Utilize Multiple Pathways To Stabilize p53

  2000cited by this paper
• The regulation of protein function by multisite phosphorylation--a 25 year update.

  2000cited by this paper
• Mitotic Effects of a Constitutively Active Mutant of the Xenopus Polo-Like Kinase Plx1

  1999cited by this paper
• Regulation of p53 Function and Stability by Phosphorylation

  1999cited by this paper
• Oxaliplatin: a review of preclinical and clinical studies.

  1998cited by this paper
• Enhanced phosphorylation of p53 by ATM in response to DNA damage.

  1998cited by this paper
• DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2.

  1997cited by this paper
• The role of p53 in cell cycle regulation.

  1996cited by this paper
• DNA damage and p53-mediated cell cycle arrest: a reevaluation.

  1996cited by this paper
• Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.

  1995cited by this paper
• WAF1, a potential mediator of p53 tumor suppression.

  1993cited by this paper
• Naturally occurring antibodies devoid of light chains

  1993cited by this paper

• No citing papers are available for this paper.